+44 20 8123 2220
info@marketpublishers.com

Hyperuricemia - Pipeline Review, H2 2020

https://marketpublishers.com/r/HC5E53D488EEN.html
Date: September 2020
Pages: 86
Price: US$ 2,000.00 (Single User License)
ID: HC5E53D488EEN

Abstracts

Hyperuricemia - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hyperuricemia - Pipeline Review, H2 2020, provides an overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape.
High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history and certain medications. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hyperuricemia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Hyperuricemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 6, 7 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1

+44 20 8123 2220
info@marketpublishers.com

molecules, respectively.

Hyperuricemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:
Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperuricemia (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Hyperuricemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Hyperuricemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Hyperuricemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline

+44 20 8123 2220
info@marketpublishers.com

projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Hyperuricemia (Metabolic Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Hyperuricemia (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Hyperuricemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

COMPANIES MENTIONED

Allena Pharmaceuticals Inc
Arthrosi Therapeutics Inc
AstraZeneca Plc
FortuneRock (China) Ltd
Hinova Pharmaceuticals Inc
J-Pharma Co Ltd
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Nippon Chemiphar Co Ltd
NuBioPharma LLC
PegBio Co Ltd
Polaris Pharmaceuticals Inc
Shanghai Yingli Pharmaceutical Co Ltd
Suzhou Sinovent Pharmaceuticals Co Ltd
Teijin Pharma Ltd
Xiuzheng Pharmaceutical Group Co Ltd

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Hyperuricemia - Pipeline Review, H2 2020

Product link: https://marketpublishers.com/r/HC5E53D488EEN.html

Price: US$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/HC5E53D488EEN.html